Mclean, United States
KeifeRx, founded in 2019, is an emerging biopharmaceutical company headquartered in the United States. The company specializes in developing innovative treatments for neurodegenerative and immune diseases using novel tyrosine kinase inhibitors (TKIs). By focusing on low-dose, orally delivered solutions, KeifeRx addresses high-need conditions, aiming for disease-modifying impacts.
The pharmaceutical innovation landscape remains critical for conditions like Alzheimer's and Parkinson's, where current treatments are insufficient. KeifeRx's approach could pave the way for more effective therapies, thus attracting attention in the Biopharma, Biotechnology, and Pharmaceutical industries.
The company raised a $6.00M Series A investment as of 01 December 2021, underscoring investor confidence in their potential. Although investor details remain undisclosed, the capital supports continued R&D efforts, accelerating the company's trajectory toward clinical deployment. This strategic infusion places KeifeRx in a promising position for future growth and partnerships.
Spero Therapeutics
